FDA Authorized First Digital Therapy for Schizophrenia
Adults with schizophrenia can now access a smartphone-based tool to address persistent negative symptoms.
Updated on Oct. 5, 2026 in Mental Health
Live Poll
Do you trust digital therapeutic apps to effectively treat complex mental health conditions?
The U.S. Food and Drug Administration has granted marketing authorization to Motivista, the first prescription digital therapeutic for negative symptoms of schizophrenia. The treatment is intended as an adjunct to clinician-managed outpatient care for adults aged 18 and older with stable positive symptoms.
Why it matters
Negative symptoms, such as social withdrawal and low motivation, are often difficult to treat and significantly impact quality of life for the estimated 60% of people with schizophrenia who experience them. This digital tool offers a new, non-pharmacological path to support daily functioning alongside existing medical care.
In the Phase 3 CONVOKE study, Motivista users showed a 62% relative improvement in negative symptoms compared to the control group after 16 weeks of use. No serious treatment-related adverse events were reported during this clinical evaluation.
The players
U.S. Food and Drug Administration
The federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices and pharmaceuticals.
Click Therapeutics
A developer of prescription digital therapeutics that combine software with clinical pathways to treat complex medical conditions.
The details
Motivista is delivered via a smartphone application that integrates psychosocial therapies with digital engagement methods. It is designed to assist patients in managing symptoms that contribute to social withdrawal and diminished motivation. By functioning as an adjunct to professional outpatient treatment, the therapy supports individuals already stabilized in their positive symptoms to improve their overall functional capacity.
Timeline
October 05, 2026: The FDA granted marketing authorization for Motivista.
16 weeks: Duration of the clinical study measurement on the CAINS-MAP scale.
Health Landscape
The emergence of prescription digital therapeutics represents an expanding frontier in mental health, shifting from traditional pharmacotherapy to software-based clinical interventions. This authorization marks a new application of prescription digital therapeutics specifically tailored for the behavioral challenges associated with schizophrenia.
If you or a loved one are managing schizophrenia, you may want to speak with your physician to determine if digital therapeutic options are appropriate for your care plan. Clinicians can provide guidance on how to incorporate such tools alongside current outpatient support and medication management.
The takeaway
Motivista offers a novel, evidence-based digital approach to managing the persistent negative symptoms of schizophrenia. Patients should consult their care team about whether this adjunct therapy fits into their long-term treatment strategy.
Further reading
For broader insight into modern approaches to behavioral care, visit the Mental Health section.
More information
You can find comprehensive details on the treatment at the Motivista official information site.
Live Poll
Do you trust digital therapeutic apps to effectively treat complex mental health conditions?
